Follow the Pundits
Tag: featured-hedge-funds
🤫 ValueAct Capital Portfolio 2026: The Quiet Activist Fund Rewiring Corporate America
ValueAct Capital doesn’t fight corporate wars in public — it quietly rewires companies from inside the boardroom. Discover the fund’s $5.9B 2026 portfolio, biggest stock bets, stealth activist strategy, and why Wall Street fears the calmest investors the most.
🏦 Alkami Technology (ALKT): The “Picks and Shovels” of Digital Banking
Alkami Technology (ALKT) isn’t a bank — it’s the digital engine powering modern banking for millions of users. After a brutal fintech reset, General Atlantic just bought another $34M worth of shares. Coincidence… or conviction?
🎩 Pershing Square USA (PSUS): IPO Drop, Insider Skill & the Ackman Question
Bill Ackman’s Pershing Square USA (PSUS) IPO promised Berkshire-style investing for the digital age—but the market responded with an 18% drop on day one. Is this a rare opportunity to buy elite hedge fund skill at a discount, or a structural trap hiding behind influence?
🐎 David Tepper’s Appaloosa Portfolio 2026: The 153% Return Playbook
David Tepper’s Appaloosa LP has delivered a staggering 153% return over three years. Here’s a breakdown of his top holdings, bold strategy shifts, and what investors can learn.
🏔️ John Paulson 2025: From "Short of the Century" to the "Long of the Decade"
John Paulson is back. After years under the radar, the legendary investor posted a 58% return in 2025—driven by high-conviction bets in biotech, gold, and strategic minerals. This is not diversification. This is precision investing.
Baillie Gifford Review 2026: The Long-Term Kings of Disruptive Growth 🏴☠️
Baillie Gifford invests like a time traveler—betting on companies that could dominate the next decade. But with great upside comes serious volatility. Here’s the full 2026 breakdown.
Ackman IPO: Genius Play or Structural Trap? 🎩📉
Bill Ackman is opening the gates to his investing empire—but is this IPO a golden ticket or a cleverly packaged trade-off? From NAV discounts to DIY replication, here’s the real audit behind the hype.
🏰 The $387 Billion Macro-Machine: Inside Fisher Investments (2026 Edition)
Fisher Investments doesn’t start with stocks—it starts with the world. With $387B under management, this macro-first powerhouse takes a very different approach to investing. Here’s what’s really going on under the hood.
Sweetgreen (SG): 90% Down—Turnaround or Trap? 🥗📉
Sweetgreen looks fresh on the menu—but the stock tells a different story. With high short interest, insider buying, and weak fundamentals, SG is a high-risk contrarian bet investors should approach carefully.
Baillie Gifford (BGKEX): 40% Returns, 7-Year Bets — Is This the Ultimate EM Growth Fund? 🌏
A 40% year, a 7-year mindset, and a bold bet on global growth—Baillie Gifford’s Emerging Markets fund might be one of the most interesting long-term plays today.